Loading...
Teva's Q2 2024 revenues reached $4.2 billion, a 7% increase in U.S. dollars or 11% in local currency, driven by generics and innovative businesses. AUSTEDO grew 32% in the U.S. The company is raising its financial guidance for 2024.
Global revenues increased by 7% to $4.2 billion, or 11% in local currency.
AUSTEDO revenues in the U.S. increased by 32%.
Non-GAAP diluted earnings per share increased to $0.61, compared to $0.56 in the second quarter of 2023.
The company raised its financial guidance for 2024.
Teva is raising its financial guidance for 2024.
Visualization of income flow from segment revenue to net income